Discover 243 paid clinical trials in Syracuse, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Syracuse is the medical research centre of central New York, and most of its trial activity runs through one institution: SUNY Upstate Medical University, the region's only academic medical centre and the largest employer in central New York. Cancer research leads the list, with ovarian cancer, lung cancer, and lymphoma studies recruiting through both cooperative groups such as the Alliance for Clinical Trials in Oncology and the National Cancer Institute and through industry sponsors, and migraine and Crohn's disease studies appear alongside them.
Filter
2
Filter results
Results: 243
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
for
Non-muscle Invasive Bladder Cancer
Location: Syracuse NY, Rochester NY, Toronto, The Bronx NY,
Sponsor: Protara Therapeutics
Sex: All
Age: 18+
Code: NCT05951179
Phase2, Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
for
Metastatic Prostate Cancer
Location: Syracuse NY, Long Island City NY, New Haven CT,
Sponsor: Janssen Research & Development, LLC
Sex: Male
Age: 18+
Code: NCT06800313
Phase1, Phase2, Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
for
Oligometastatic Prostate Cancer (OMPC)
Location: Syracuse NY, Ottawa, Toronto, The Bronx NY, New York NY,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT05939414
Phase3, Recruiting
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG,
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
for
Prostate Cancer
Location: Syracuse NY, The Bronx NY, Hartford CT, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT06780670
Phase2, Phase3, Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Location: Syracuse NY, North Hills NY, Lancaster PA,
Sponsor: Dendreon
Sex: Male
Age: 18+
Code: NCT06134232
Phase2, Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for
Metastatic Castration-resistant Prostate Cancer (mCRPC),